Nam Soo Lee

Publications (2)2.63 Total impact

• Source

  Available from: koreamed.org

  Article: [A case of therapy-related acute monocytic leukemia following low-dose of etoposide treatment for hemophagocytic lymphohistiocytosis].

  Young Ik Seo, Rojin Park, Tae Youn Choi, Jeung Won Shin, Jong Ho Won, Hee Sook Park, Nam Soo Lee, Duck Cho
  [show abstract] [hide abstract]
  ABSTRACT: We report a case of therapy-related acute myeloid leukemia after low-dosed topoisomerase II inhibitor (etoposide) treatment for hemophagocytic lymphohistiocytosis (HLH). A 62-yr-old female patient had previously been treated with a HLH-94 protocol containing a low-dose of etoposide (total dose of 300 mg/m2). Thirty-one months later, the patient was admitted to the hematology department with general weakness and upper respiratory infection symptoms. Peripheral blood smear and bone marrow study revealed acute monocytic leukemia. There was no evidence of myelodysplastic syndrome, and a cytogenetic study showed no chromosomal abnormalities.
  The Korean Journal of Laboratory Medicine 09/2007; 27(4):244-7. · 0.63 Impact Factor
• Article: Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer.

  Kihyun Kim, Eunmi Nam, Nam Soo Lee, Hye Ran Lee, Jee Yun Lee, Hyo Rak Lee, Se Hoon Park, Sung Yong Oh, Ji Hyang Kim, Seo Young Song, Joon Oh Park, Won Seog Kim, Chul Won Jung, Young-Hyuk Im, Mark H Lee, Woo Yong Lee, Hokyung Chun, Chan H Park, Keunchil Park, Won Ki Kang
  [show abstract] [hide abstract]
  ABSTRACT: A phase II study was performed to evaluate the clinical efficacy and toxicity of oxaliplatin combined with uracil and tegafur (UFT) in patients with advanced colorectal cancer previously treated with a fluoropyrimidine-based regimen. From January to December 1999, 34 patients were enrolled in this study. Patients received intravenous oxaliplatin 130 mg/m2 on day 1 and daily oral UFT 350 mg/m2 in 3 divided doses for 21 days and repeated every 21 days. Thirty-one of 34 patients were assessable for response and 32 patients for toxicity. Partial response was observed in four patients and stable disease in six patients. The response rate was 12.9% (95% CI, 3.6-29.8%) and median duration of response was 17 weeks. The median overall survival and progression-free survival of all patients were 26 weeks (range, 3-90+ weeks) and 9 weeks (range, 3-56 weeks), respectively. Sensory neuropathy was the most common toxicity, but there was no severe toxicity (>grade II) except for a case of grade III neutropenia. We conclude that oxaliplatin and UFT combination chemotherapy was well tolerated without significant toxicities. The results of this trial will serve as the basis for designing new clinical trials with a different dose or schedule.
  American Journal of Clinical Oncology 08/2002; 25(4):354-7. · 2.01 Impact Factor